-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Kidney stones are a common problem with an estimated global prevalence of up to 15%
diabetes
A recent observational study found that sodium-glucose cotransporter 2 inhibitors were associated with a 49% lower risk of kidney stones in patients with type 2 diabetes compared with GLP-1 receptor agonists
We pooled data from 20 phase I-IV trials, including the large CV outcomes trial EMPA-REGOUTCOME, on 15,081 patients with type 2 diabetes who were randomized to empagliflozin (n=10177) or placebo ( n=4904) treatment
Median exposure to study drug was 543 days (placebo) and 549 days (empagliflozin)
Thus, the underlying mechanisms remain unclear, and dedicated randomized prospective clinical trials are warranted to confirm these preliminary observations in patients with and without type 2 diabetes
Thus, the underlying mechanisms remain unclear, and dedicated randomized prospective clinical trials are warranted to confirm these preliminary observations in patients with and without type 2 diabetes
Original source:
Priyadarshini Balasubramanian, et al.
Empagliflozin and decreased risk of nephrolithiasis: A potential new role for SGLT2 inhibition?
Leave a comment here